Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.
Marie-Christin HoffmannGiulio CavalliNatalie FadleEleonora CantoniEvi RegitzOctavian FleserPhilipp KlemmMarina ZaksElisabeth StögerCorrado CampochiaroAlessandro TomelleriElena BaldisseraJörg Thomas BittenbringVincent ZimmerJochen PfeiferYvan FischerKlaus-Dieter PreussMoritz BewarderBernhard ThurnerSabrina FuehnerDirk FoellLorenzo DagnaChristoph KesselLorenz ThurnerPublished in: Journal of clinical immunology (2024)
Autoantibodies neutralizing IL-1Ra may represent a novel patho-mechanism in a subgroup of Still's disease patients, which is sensitive to high-dose IL-1 blocking therapy.
Keyphrases
- high dose
- end stage renal disease
- rheumatoid arthritis
- chronic kidney disease
- newly diagnosed
- systemic lupus erythematosus
- low dose
- prognostic factors
- randomized controlled trial
- cancer therapy
- peritoneal dialysis
- ankylosing spondylitis
- mesenchymal stem cells
- drug delivery
- dengue virus
- interstitial lung disease
- systemic sclerosis
- zika virus
- idiopathic pulmonary fibrosis
- human health